AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32338946 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 90
Study 36103260 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine 50mcg daily
Number of subjects: 940
Study 36103260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 940
Study 36103260 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated SCH/OH
Number of subjects: 940
Study 36103260 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid women
Number of subjects: 940
Study 36103260 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid groups
Number of subjects: 940
Study 34243940 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-guided anaesthesia
Number of subjects: 1232
Study 34243940 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1232
Study 32552691 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-ramped position
Number of subjects: 60
Study 32552691 — intervention group
Group type: COMPARATOR
Intervention: Ramped position
Number of subjects: 60
Study 33827424 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of EVD
Number of subjects: 510
Study 33827424 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of exposure to infection
Number of subjects: 510
Study 33827424 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-seeking behavior
Number of subjects: 510
Study 32310676 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular yellow indication (CY)
Number of subjects: 45
Study 32310676 — intervention group
Group type: COMPARATOR
Intervention: Following vehicle type (heavy vehicle vs passenger car)
Number of subjects: 45
Study 32310676 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to stop line
Number of subjects: 45
Study 36364740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fig leaf tea
Number of subjects: 15
Study 36364740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 35545414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sticker group
Number of subjects: 67
Study 35545414 — intervention group
Group type: COMPARATOR
Intervention: Marker pen group
Number of subjects: 67
Study 32026435 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 50
Study 32026435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 35449097 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser hemorrhoidoplasty (LHP) only
Number of subjects: 76
Study 35449097 — intervention group
Group type: COMPARATOR
Intervention: Laser hemorrhoidoplasty with hemorrhoidal artery ligation (HAL)
Number of subjects: 76
Study 34387431 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior subtotal vertebral body resection + titanium mesh reconstruction + screw rod internal fixation (Group A)
Number of subjects: 32
Study 34387431 — intervention group
Group type: COMPARATOR
Intervention: Posterior 270° ring decompression of vertebral canal + titanium mesh reconstruction + screw rod internal fixation (Group B)
Number of subjects: 32
Study 34387431 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 32
Study 36111858 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 576
Study 36111858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 33397459 — intervention group
Group type: EXPERIMENTAL
Intervention: Palate surgery at 6 months of age
Number of subjects: 0
Study 33397459 — intervention group
Group type: COMPARATOR
Intervention: Palate surgery at 12 months of age
Number of subjects: 0
Study 35679826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task Zumba Gold (DTZ)
Number of subjects: 60
Study 35679826 — intervention group
Group type: COMPARATOR
Intervention: Health education (Control)
Number of subjects: 60
Study 35645079 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - light cure resin cement - Variolink N LC by Ivoclar Vivadent in clear shade
Number of subjects: 60
Study 35645079 — intervention group
Group type: COMPARATOR
Intervention: Group B - base paste of dual‐cure resin cement - Variolink N by Ivoclar Vivadent in transparent shade
Number of subjects: 60
Study 35645079 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C - dual‐cure resin cement - Clearfil esthetic cement EX by Kuraray in clear shade
Number of subjects: 60
Study 32927895 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast eating (10 min)
Number of subjects: 19
Study 32927895 — intervention group
Group type: COMPARATOR
Intervention: Slow eating (20 min)
Number of subjects: 19
Study 33109913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 861
Study 33109913 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 861
Study 33910487 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 254
Study 33910487 — intervention group
Group type: COMPARATOR
Intervention: CBT enriched with emotion regulation training (ENCERT)
Number of subjects: 254
Study 32301591 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg/day
Number of subjects: 203
Study 32301591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 33993136 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced oral care (intervention units)
Number of subjects: 8709
Study 33993136 — intervention group
Group type: COMPARATOR
Intervention: Usual oral care (control units)
Number of subjects: 8709
Study 32804957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated sewage sludge (DSS) application
Number of subjects: 24
Study 32804957 — intervention group
Group type: COMPARATOR
Intervention: No dehydrated sewage sludge (DSS) application
Number of subjects: 24
Study 35947288 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention with bioimpedance spectroscopy (BIS) and a compression garment applied for 12 hours a day over 4 weeks
Number of subjects: 2907
Study 35947288 — intervention group
Group type: COMPARATOR
Intervention: Tape measurement coupled with early intervention
Number of subjects: 2907
Study 32325012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (ciprofloxacin 750 mg every 12 h and metronidazole 250 mg every 8 h the day before surgery)
Number of subjects: 565
Study 32325012 — intervention group
Group type: COMPARATOR
Intervention: No oral antibiotics (control group)
Number of subjects: 565
Study 32325012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (experimental group)
Number of subjects: 565
Study 35103815 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing technique (G1; n = 20)
Number of subjects: 43
Study 35103815 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (G2; n = 23)
Number of subjects: 43
Study 33719478 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 60
Study 33719478 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 60
Study 32400732 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional massage in addition to routine physical therapy (once daily, five times a week for three months)
Number of subjects: 86
Study 32400732 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy (once daily, five times a week for three months)
Number of subjects: 86
Study 35728048 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat + azacitidine (n = 227)
Number of subjects: 554
Study 35728048 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine monotherapy (n = 227)
Number of subjects: 554
Study 32947067 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PE rehabilitation intervention
Number of subjects: 26
Study 35689281 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership in iSupport program
Number of subjects: 185
Study 35689281 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 185
Study 33574974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus dexmedetomidine
Number of subjects: 40
Study 33574974 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 40
Study 32479807 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcon model SN60WF
Number of subjects: 195
Study 32479807 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoya model XY‐1
Number of subjects: 195
Study 32479807 — intervention group
Group type: EXPERIMENTAL
Intervention: AMO model ZCB00V
Number of subjects: 195
Study 36115850 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Number of subjects: 100
Study 36115850 — intervention group
Group type: COMPARATOR
Intervention: ChAdOx1
Number of subjects: 100
Study 36115850 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous schedule
Number of subjects: 100
Study 33028132 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan with autologous stem cell transplantation
Number of subjects: 0
Study 33028132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-based regimens
Number of subjects: 0
Study 33028132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 33028132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib
Number of subjects: 0
Study 33028132 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Number of subjects: 0
Study 33028132 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 33028132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Number of subjects: 0
Study 33028132 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 0
Study 33028132 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Number of subjects: 0
Study 33028132 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab
Number of subjects: 0
Study 33028132 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 0
Study 33028132 — intervention group
Group type: EXPERIMENTAL
Intervention: NEOD001
Number of subjects: 0
Study 33028132 — intervention group
Group type: EXPERIMENTAL
Intervention: Melflufen
Number of subjects: 0
Study 36437902 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (real HF-rTMS)
Number of subjects: 64
Study 36437902 — intervention group
Group type: COMPARATOR
Intervention: Sham group (sham HF-rTMS)
Number of subjects: 64
Study 36437902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (active and sham)
Number of subjects: 64
Study 32902668 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal dexamethasone (8 mg)
Number of subjects: 30
Study 32902668 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexamethasone (8 mg)
Number of subjects: 30
Study 35641979 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making Assistant application
Number of subjects: 180
Study 35641979 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 36413261 — intervention group
Group type: EXPERIMENTAL
Intervention: UP446
Number of subjects: 50
Study 36413261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 33515745 — intervention group
Group type: EXPERIMENTAL
Intervention: GoreTex (2-0 GoreTex)
Number of subjects: 200
Study 33515745 — intervention group
Group type: COMPARATOR
Intervention: PDS (2-0 PDS)
Number of subjects: 200
Study 33515745 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (GoreTex and PDS)
Number of subjects: 200
Study 33752252 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 52
Study 33752252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 32020470 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFields/TMZ
Number of subjects: 39
Study 32020470 — intervention group
Group type: COMPARATOR
Intervention: TMZ alone
Number of subjects: 39
Study 36107667 — intervention group
Group type: EXPERIMENTAL
Intervention: Long COVID description
Number of subjects: 1110
Study 36107667 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom uncertainty emphasized
Number of subjects: 1110
Study 36107667 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced support
Number of subjects: 1110
Study 36107667 — intervention group
Group type: COMPARATOR
Intervention: Ongoing COVID-19 recovery description
Number of subjects: 1110
Study 36107667 — intervention group
Group type: COMPARATOR
Intervention: Symptom uncertainty not emphasized
Number of subjects: 1110
Study 36107667 — intervention group
Group type: COMPARATOR
Intervention: Basic support
Number of subjects: 1110
Study 32994490 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA)
Number of subjects: 70
Study 32994490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 36098362 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus Bifidobacterium animalis subsp. lactis (BB‐12) probiotic (MET-PRO group)
Number of subjects: 156
Study 36098362 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone (MET group)
Number of subjects: 156
Study 35725247 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training at home (once a week in SLT office plus one or three times per week at home)
Number of subjects: 0
Study 35725247 — intervention group
Group type: COMPARATOR
Intervention: Regular condition (once a week in SLT office only)
Number of subjects: 0
Study 35725247 — intervention group
Group type: EXPERIMENTAL
Intervention: Training frequency (once a week in SLT office plus one or three times per week at home)
Number of subjects: 0
Study 33811308 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (200 mg)
Number of subjects: 92
Study 33811308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 32972311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation intervention
Number of subjects: 51
Study 32972311 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic relationship
Number of subjects: 51
Study 34328440 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group (mHealth tool with real-time quality feedback)
Number of subjects: 21
Study 34328440 — intervention group
Group type: COMPARATOR
Intervention: Basic group (mHealth tool without real-time quality feedback)
Number of subjects: 21
Study 32605239 — intervention group
Group type: EXPERIMENTAL
Intervention: U-shaped automatic electric toothbrush (U)
Number of subjects: 22
Study 32605239 — intervention group
Group type: COMPARATOR
Intervention: Conventional powered toothbrush (P)
Number of subjects: 22
Study 32605239 — intervention group
Group type: COMPARATOR
Intervention: Habitual toothbrushing procedure (H)
Number of subjects: 22
Study 32605239 — intervention group
Group type: COMPARATOR
Intervention: No brushing (N)
Number of subjects: 22
Study 36181480 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-mg testosterone cypionate (weekly intramuscular injections)
Number of subjects: 142
Study 36181480 — intervention group
Group type: COMPARATOR
Intervention: Placebo (weekly intramuscular injections)
Number of subjects: 142
Study 34452930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 905
Study 34452930 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks
Number of subjects: 905
Study 33645312 — intervention group
Group type: EXPERIMENTAL
Intervention: Text processing + foundational skills (n = 117)
Number of subjects: 364
Study 33645312 — intervention group
Group type: EXPERIMENTAL
Intervention: Text processing only (n = 120)
Number of subjects: 364
Study 33645312 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 127)
Number of subjects: 364
Study 34176722 — intervention group
Group type: EXPERIMENTAL
Intervention: CNSA-001 (sepiapterin, PTC923) 10 mg/kg BID for 14 days
Number of subjects: 0
Study 34176722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32590251 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve radiofrequency thermocoagulation (PRF) via the foramen rotundum and foramen ovale
Number of subjects: 102
Study 32590251 — intervention group
Group type: COMPARATOR
Intervention: Semilunar ganglion radiofrequency thermocoagulation (GRF)
Number of subjects: 102
Study 33293114 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial threading (3 sessions every 21 days)
Number of subjects: 18
Study 35278283 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg administered via autoinjector (AI)
Number of subjects: 130
Study 35278283 — intervention group
Group type: COMPARATOR
Intervention: Dupilumab 200 mg administered via prefilled syringe with needle shield (PFS-S)
Number of subjects: 130
Study 34507265 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI (Body Mass Index)
Number of subjects: 339224
Study 34370330 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement pattern training (MoveTrain)
Number of subjects: 27
Study 34370330 — intervention group
Group type: COMPARATOR
Intervention: Standard strength and flexibility training (Standard)
Number of subjects: 27
Study 33310803 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator Cuff Unloading Exercise Programme
Number of subjects: 78
Study 33310803 — intervention group
Group type: COMPARATOR
Intervention: Rotator Cuff Loading Exercise Programme
Number of subjects: 78
Study 35310181 — intervention group
Group type: EXPERIMENTAL
Intervention: DVT general prevention + basic physical prevention + NMES
Number of subjects: 278
Study 35310181 — intervention group
Group type: COMPARATOR
Intervention: DVT general prevention + basic physical prevention
Number of subjects: 278
Study 37605078 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic transforaminal discectomy (PETD)
Number of subjects: 113
Study 37605078 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic interlaminar discectomy (PEID)
Number of subjects: 113
Study 37605078 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 113
Study 32553428 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg enalapril and 0.8 mg folic acid
Number of subjects: 10699
Study 32553428 — intervention group
Group type: COMPARATOR
Intervention: 10 mg enalapril alone
Number of subjects: 10699
Study 32054896 — intervention group
Group type: EXPERIMENTAL
Intervention: Instability resistance training
Number of subjects: 68
Study 32054896 — intervention group
Group type: COMPARATOR
Intervention: Stable machine-based resistance training
Number of subjects: 68
Study 34024505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention menu with culinary improvements (popular meals-on-wheels, main meal for dinner, starter/dessert)
Number of subjects: 52
Study 34024505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention menu with culinary improvements
Number of subjects: 52
Study 34024505 — intervention group
Group type: COMPARATOR
Intervention: Non-optimized menu (control group)
Number of subjects: 52
Study 36462699 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive methodology for evaluating CRS performance
Number of subjects: 0
Study 36462699 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted messaging relating to performance metrics
Number of subjects: 0
Study 32602744 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Meibomian gland expression
Number of subjects: 44
Study 32602744 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 44
Study 33291649 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 L/day of an artificially sweetened soft drink containing acesulfame K (950) and aspartame (951) for 2 weeks
Number of subjects: 39
Study 33291649 — intervention group
Group type: COMPARATOR
Intervention: 0.6 L/day of mineral water for 2 weeks
Number of subjects: 39
Study 33291649 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring during each 2 week period
Number of subjects: 39
Study 33671093 — intervention group
Group type: EXPERIMENTAL
Intervention: LEA with low protein (LEA-LP; 0.8 g protein·kg BW-1)
Number of subjects: 7
Study 33671093 — intervention group
Group type: EXPERIMENTAL
Intervention: LEA with high protein (LEA-HP; 1.7 g protein·kg BW-1)
Number of subjects: 7
Study 33671093 — intervention group
Group type: COMPARATOR
Intervention: Control (CON; 40 kcal·kg FFM-1·day-1, 1.7 g protein·kg BW-1)
Number of subjects: 7
Study 33671093 — intervention group
Group type: EXPERIMENTAL
Intervention: LEA (both LEA-LP and LEA-HP)
Number of subjects: 7
Study 33671093 — intervention group
Group type: EXPERIMENTAL
Intervention: LEA-LP vs LEA-HP
Number of subjects: 7
Study 33087055 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (L‐selenomethionine) 200 μg/day for 3 months
Number of subjects: 100
Study 33087055 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing, in addition to recommended therapy)
Number of subjects: 100
Study 32100501 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with penetrating moxibustion
Number of subjects: 60
Study 32100501 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback electrical stimulation
Number of subjects: 60
Study 35665800 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision prevention materials incorporating melanocortin‐1 receptor genetic risk information
Number of subjects: 1134
Study 35665800 — intervention group
Group type: COMPARATOR
Intervention: Generic prevention materials
Number of subjects: 1134
Study 33283579 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 1050
Study 33283579 — intervention group
Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 1050
Study 35450203 — intervention group
Group type: EXPERIMENTAL
Intervention: SGB combined with 0.25% lidocaine (Group A)
Number of subjects: 90
Study 35450203 — intervention group
Group type: EXPERIMENTAL
Intervention: SGB combined with 0.5% lidocaine (Group B)
Number of subjects: 90
Study 35450203 — intervention group
Group type: EXPERIMENTAL
Intervention: SGB combined with 0.75% lidocaine (Group C)
Number of subjects: 90
Study 34293081 — intervention group
Group type: COMPARATOR
Intervention: Low-SAA group (n=20)
Number of subjects: 40
Study 34293081 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SAA group (n=20)
Number of subjects: 40
Study 34293081 — intervention group
Group type: COMPARATOR
Intervention: Cold rice
Number of subjects: 40
Study 34293081 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot rice
Number of subjects: 40
Study 34293081 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SAA group (n=19)
Number of subjects: 40